Grifols S.A (G0FB) - Net Assets
Based on the latest financial reports, Grifols S.A (G0FB) has net assets worth €7.60 Billion EUR (≈ $8.89 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€19.71 Billion ≈ $23.05 Billion USD) and total liabilities (€12.11 Billion ≈ $14.16 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Grifols S.A tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.60 Billion |
| % of Total Assets | 38.57% |
| Annual Growth Rate | 8.24% |
| 5-Year Change | -6.68% |
| 10-Year Change | N/A |
| Growth Volatility | 18.4 |
Grifols S.A - Net Assets Trend (2016–2025)
This chart illustrates how Grifols S.A's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Grifols S.A to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Grifols S.A (2016–2025)
The table below shows the annual net assets of Grifols S.A from 2016 to 2025. For live valuation and market cap data, see market value of Grifols S.A.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €7.60 Billion ≈ $8.89 Billion |
-11.67% |
| 2024-12-31 | €8.61 Billion ≈ $10.06 Billion |
+14.55% |
| 2023-12-31 | €7.51 Billion ≈ $8.78 Billion |
-11.16% |
| 2022-12-31 | €8.46 Billion ≈ $9.89 Billion |
+3.81% |
| 2021-12-31 | €8.15 Billion ≈ $9.52 Billion |
+21.23% |
| 2020-12-31 | €6.72 Billion ≈ $7.86 Billion |
-1.84% |
| 2019-12-31 | €6.85 Billion ≈ $8.00 Billion |
+45.76% |
| 2018-12-31 | €4.70 Billion ≈ $5.49 Billion |
+29.24% |
| 2017-12-31 | €3.63 Billion ≈ $4.25 Billion |
-2.52% |
| 2016-12-31 | €3.73 Billion ≈ $4.36 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Grifols S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €300.00 Million | 5.69% |
| Other Components | €4.97 Billion | 94.31% |
| Total Equity | €5.27 Billion | 100.00% |
Grifols S.A Competitors by Market Cap
The table below lists competitors of Grifols S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GCL Energy Technology Co Ltd
SHE:002015
|
$4.43 Billion |
|
Capricorn Metals Ltd
AU:CMM
|
$4.43 Billion |
|
Kunshan Dongwei Technology Co Ltd
SHG:688700
|
$4.43 Billion |
|
Henan Yuneng Holdings Co Ltd
SHE:001896
|
$4.43 Billion |
|
LG Uplus
KO:032640
|
$4.42 Billion |
|
Jiangsu King's Luck Brewery Joint-Stock Co Ltd
SHG:603369
|
$4.42 Billion |
|
Wex Inc
NYSE:WEX
|
$4.42 Billion |
|
ENTAIN PLC UNSP.ADR/1
F:6GI0
|
$4.42 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Grifols S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,883,727,000 to 5,271,000,000, a change of -612,727,000 (-10.4%).
- Net income of 402,000,000 contributed positively to equity growth.
- Dividend payments of 128,000,000 reduced retained earnings.
- Other factors decreased equity by 886,727,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €402.00 Million | +7.63% |
| Dividends Paid | €128.00 Million | -2.43% |
| Other Changes | €-886.73 Million | -16.82% |
| Total Change | €- | -10.41% |
Book Value vs Market Value Analysis
This analysis compares Grifols S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.83x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.20x to 0.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €5.31 | €6.40 | x |
| 2018-12-31 | €6.15 | €6.40 | x |
| 2019-12-31 | €7.05 | €6.40 | x |
| 2020-12-31 | €7.46 | €6.40 | x |
| 2021-12-31 | €8.98 | €6.40 | x |
| 2022-12-31 | €9.04 | €6.40 | x |
| 2023-12-31 | €7.91 | €6.40 | x |
| 2024-12-31 | €8.65 | €6.40 | x |
| 2025-12-31 | €7.74 | €6.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Grifols S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.63%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.34%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 3.74x
- Recent ROE (7.63%) is below the historical average (9.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 14.66% | 13.47% | 0.40x | 2.72x | €173.31 Million |
| 2017 | 18.26% | 15.35% | 0.40x | 3.01x | €299.79 Million |
| 2018 | 14.12% | 13.30% | 0.36x | 2.95x | €174.09 Million |
| 2019 | 12.96% | 12.26% | 0.33x | 3.22x | €142.93 Million |
| 2020 | 13.88% | 13.28% | 0.35x | 2.99x | €198.15 Million |
| 2021 | 3.00% | 3.71% | 0.26x | 3.15x | €-426.86 Million |
| 2022 | 3.40% | 3.43% | 0.28x | 3.51x | €-404.71 Million |
| 2023 | 0.78% | 0.64% | 0.31x | 3.91x | €-494.84 Million |
| 2024 | 2.67% | 2.18% | 0.34x | 3.64x | €-431.37 Million |
| 2025 | 7.63% | 5.34% | 0.38x | 3.74x | €-125.10 Million |
Industry Comparison
This section compares Grifols S.A's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $197,404,872,556
- Average return on equity (ROE) among peers: 14.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Grifols S.A (G0FB) | €7.60 Billion | 14.66% | 1.59x | $4.42 Billion |
| Bayer AG NA (BAYN) | $47.52 Billion | 8.61% | 1.66x | $36.43 Billion |
| Cosmo Pharmaceuticals N.V (C43) | $463.79 Million | 3.71% | 0.64x | $1.51 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $19.52 Billion | 19.03% | 0.35x | $9.80 Billion |
| CSPC PHARMACEUT.GR. ADR4 (CVGU) | $31.64 Billion | 19.25% | 0.32x | $11.04 Billion |
| GRIFOLS ADR 1/2/EO-50 (G0F) | $8.61 Billion | 1.82% | 1.49x | $4.21 Billion |
| GSK PLC SP. ADR/2 NEW (GS70) | $12.79 Billion | 38.52% | 3.61x | $101.34 Billion |
| ORION CORP.B UNSP.ADR 1/2 (OFK0) | $1.00 Billion | 32.83% | 0.62x | $8.31 Billion |
| Sanofi (SNW2) | $59.11 Billion | 4.75% | 0.91x | $105.07 Billion |
| ASTELLAS PHARMA UNSP.ADR (YPHA) | $1.60 Trillion | 1.07% | 1.24x | $19.55 Billion |
About Grifols S.A
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, … Read more